Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02910999
What this trial is testing

Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 868
Testing effectiveness (Phase 2)Study completedNCT02250326
What this trial is testing

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Celgene 240
Early research (Phase 1)Study completedNCT00857025
What this trial is testing

Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
City of Hope Medical Center 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305
Large-scale testing (Phase 3)Active Not RecruitingNCT05607550
What this trial is testing

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Who this might be right for
Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations
ArriVent BioPharma, Inc. 398
Large-scale testing (Phase 3)Study completedNCT04303780
What this trial is testing

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Who this might be right for
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Amgen 345
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Looking for participantsNCT06962865
What this trial is testing

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
RemeGen Co., Ltd. 80
Testing effectiveness (Phase 2)Looking for participantsNCT06051695
What this trial is testing

Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNSCLC+17 more
A2 Biotherapeutics Inc. 474
Testing effectiveness (Phase 2)Study completedNCT02108964
What this trial is testing

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Who this might be right for
Advanced Non-small Cell Lung Cancer
Novartis Pharmaceuticals 225
Large-scale testing (Phase 3)UnknownNCT05111197
What this trial is testing

Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy

Who this might be right for
Locally Advanced Non Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Institut Cancerologie de l'Ouest 112
Testing effectiveness (Phase 2)Looking for participantsNCT06668103
What this trial is testing

Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd 54
Large-scale testing (Phase 3)Active Not RecruitingNCT06635824
What this trial is testing

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Who this might be right for
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Genmab 191
Testing effectiveness (Phase 2)Study completedNCT00043823
What this trial is testing

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 41
Large-scale testing (Phase 3)Study completedNCT04206072
What this trial is testing

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerEGFR Gene Mutation
Betta Pharmaceuticals Co., Ltd. 362
Not applicableStudy completedNCT00900172
What this trial is testing

Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel

Who this might be right for
Lung Cancer
ECOG-ACRIN Cancer Research Group 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07752875
What this trial is testing

LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

Who this might be right for
Ovarian CancerSmall Cell Lung CancerNon Small Cell Lung Cancer+7 more
LG Chem 250
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06672068
What this trial is testing

TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

Who this might be right for
NSCLC
TYK Medicines, Inc 60
Large-scale testing (Phase 3)Not Yet RecruitingNCT07680790
What this trial is testing

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 850
Testing effectiveness (Phase 2)Looking for participantsNCT07518160
What this trial is testing

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Who this might be right for
Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Shanghai Junshi Bioscience Co., Ltd. 35
Next Page